ES3022913T3 - Solid forms of a cdk4 inhibitor - Google Patents
Solid forms of a cdk4 inhibitor Download PDFInfo
- Publication number
- ES3022913T3 ES3022913T3 ES21783049T ES21783049T ES3022913T3 ES 3022913 T3 ES3022913 T3 ES 3022913T3 ES 21783049 T ES21783049 T ES 21783049T ES 21783049 T ES21783049 T ES 21783049T ES 3022913 T3 ES3022913 T3 ES 3022913T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- ppm
- crystalline form
- values
- monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3022913T3 true ES3022913T3 (en) | 2025-05-29 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21783049T Active ES3022913T3 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020336309A1 (en) | 2019-08-26 | 2022-03-17 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CA3240993A1 (en) * | 2021-12-02 | 2023-06-08 | Pfizer Inc | Cdk4 inhibitor for the treatment of cancer |
| JP2025533719A (ja) | 2022-07-29 | 2025-10-09 | ファイザー・インク | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン |
| WO2024201334A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2025024388A1 (en) | 2023-07-21 | 2025-01-30 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| KR102587758B1 (ko) * | 2016-07-13 | 2023-10-12 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
| CU24522B1 (es) | 2016-08-15 | 2021-06-08 | Pfizer | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS |
| MA52360B1 (fr) * | 2018-04-26 | 2025-05-30 | Pfizer Inc. | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines |
-
2021
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL4214202T3 (pl) | 2025-05-19 |
| JP7260606B2 (ja) | 2023-04-18 |
| DK4214202T3 (da) | 2025-03-31 |
| EP4578450A2 (en) | 2025-07-02 |
| KR20230069983A (ko) | 2023-05-19 |
| JP7291839B2 (ja) | 2023-06-15 |
| AU2021345531B2 (en) | 2024-02-29 |
| AU2021345531A1 (en) | 2023-04-20 |
| EP4578450A3 (en) | 2025-07-16 |
| EP4214202B1 (en) | 2025-02-26 |
| JP2022049005A (ja) | 2022-03-28 |
| TWI809503B (zh) | 2023-07-21 |
| HUE070846T2 (hu) | 2025-07-28 |
| MX2023003054A (es) | 2023-04-05 |
| BR112023004713A2 (pt) | 2023-04-18 |
| PT4214202T (pt) | 2025-04-11 |
| ZA202303655B (en) | 2024-09-25 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4214202A1 (en) | 2023-07-26 |
| WO2022058871A1 (en) | 2022-03-24 |
| SI4214202T1 (sl) | 2025-05-30 |
| TW202334125A (zh) | 2023-09-01 |
| TW202216698A (zh) | 2022-05-01 |
| JP2022186995A (ja) | 2022-12-15 |
| CN116507620A (zh) | 2023-07-28 |
| CA3195063A1 (en) | 2022-03-24 |
| FI4214202T3 (fi) | 2025-04-25 |
| CN116507620B (zh) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3022913T3 (en) | Solid forms of a cdk4 inhibitor | |
| TWI823213B (zh) | Cdk2抑制劑之固體形式 | |
| KR20240145475A (ko) | 고형 종양의 치료를 위한 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제 | |
| WO2022034504A1 (en) | Combination therapy | |
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| WO2022226052A1 (en) | Pi3k inhibitors, nanoformulations, and uses thereof | |
| RU2850825C1 (ru) | Твердые формы ингибитора cdk2 | |
| BR112023004713B1 (pt) | Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica | |
| HK40087859A (zh) | Cdk4抑制剂的固体形式 | |
| HK1233924B (en) | Derivatives of cephalosporin for treating cancer | |
| HK1233924A1 (en) | Derivatives of cephalosporin for treating cancer |